Biofrontera Q1 2024 GAAP EPS $(2.88) Misses $(1.17) Estimate, Sales $7.912M Miss $10.857M Estimate

5/15/24 5:19:27 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BFRI alert in real time by email

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(2.88) per share which missed the analyst consensus estimate of $(1.17) by 146.15 percent. This is a 48.57 percent increase over losses of $(5.60) per share from the same period last year. The company reported quarterly sales of $7.912 million which missed the analyst consensus estimate of $10.857 million by 27.12 percent. This is a 9.40 percent decrease over sales of $8.733 million the same period last year.

Get the next $BFRI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BFRI

Date	Price Target	Rating	Analyst
12/15/2021	$11.00	Buy	Benchmark
11/24/2021	$20.00	Buy	Roth Capital

More analyst ratings

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and opportunity for specialized sales and marketing approaches resulting from an evolving landscape of medical practices consolidating into larger integrated organizations.Reporting to Mark Baldyga, Vice President of Sales and Marketing, Ms. Widdicombe joins Biofrontera with over
8/29/23 8:00:00 AM ET
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care
Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors
WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.Dr. Lanckriet was nominated to Biofrontera Inc.'s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company's Current Report o
7/12/23 8:00:00 AM ET
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care
Biofrontera Inc. Announces Resignation of CEO
Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company's Strategic Plan and 2023 Commercial GoalsWOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the resignation of Erica Monaco as Chief Executive Officer, which will be effective pending the completion of a near term transition of responsibilities with the Board of Directors. Hermann Luebbert, Biofrontera's Executive Chairman and founder, will assume the CEO responsibilities. Ms. Monaco intends to pursue other professional opportunities and her resignation did not res
5/12/23 7:00:00 AM ET
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care

$BFRI
Press Releases

Fastest customizable press release news feed in the world

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ●Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%. ●Ameluz® achieved record volume in September 2024. ●Organization continues to prudently manage SG&A expenses in line with business needs with a reduction of 14% in the first 9 months of 2024 vs 2023. ●Cash and cash equivalents were $2.9 million as of September 30, 2
11/13/24 5:15:00 PM ET
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.Conference Call and Webcast InformationEvent:Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference CallDate:Thursday, November 14, 2024Time:10:00am ETConference Call:1-877-
11/1/24 11:55:00 AM ET
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant p<0.0001Correlates to data seen in Europe where sBCC is already incorporated in the Summary of Product Characteristics.BCC is the most common skin cancer in the US, with more than 3 million cases each year1. WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, today announced top-line results in its Phase 3 study of the use of Ameluz® with the BF-RhodoLED® lamp in the treatment of sBCC (study ALA-BCC-CT013)
10/31/24 10:32:00 AM ET
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care

$BFRI
Financials

Live finance-specific insights

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ●Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%. ●Ameluz® achieved record volume in September 2024. ●Organization continues to prudently manage SG&A expenses in line with business needs with a reduction of 14% in the first 9 months of 2024 vs 2023. ●Cash and cash equivalents were $2.9 million as of September 30, 2
11/13/24 5:15:00 PM ET
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.Conference Call and Webcast InformationEvent:Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference CallDate:Thursday, November 14, 2024Time:10:00am ETConference Call:1-877-
11/1/24 11:55:00 AM ET
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update. Highlights from the second quarter of 2024 and subsequent weeks included the following: Total revenues for the second quarter of 2024 were $7.8 million, a 34% increase from the same period of the prior yearCash and cash equivalents were $4.4 million as of June 30, 2024, compared with $1.3 million on December 31, 2023Biofrontera announced the launch of a new, FDA-approved red-light sour
8/14/24 4:30:00 PM ET
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care

Biofrontera Q1 2024 GAAP EPS $(2.88) Misses $(1.17) Estimate, Sales $7.912M Miss $10.857M Estimate

Chat with this insight

Recent Analyst Ratings for $BFRI

$BFRI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Benchmark initiated coverage on Biofrontera with a new price target

Roth Capital initiated coverage on Biofrontera with a new price target

$BFRI SEC Filings

Biofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form S-8 filed by Biofrontera Inc.

Biofrontera Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$BFRI Leadership Updates

Live Leadership Updates

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

Biofrontera Inc. Announces Resignation of CEO

$BFRI Press Releases

Fastest customizable press release news feed in the world

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

$BFRI Market Insights

Live Market Insights

$BFRI Large Ownership Changes

This live feed shows all institutional transactions in real time.

$BFRI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Biofrontera shares are trading higher after the company launched the RhodoLED XL lamp.

Biofrontera Launches A New, FDA-Approved Red Light Source, The RhodoLED XL Lamp